When will companies stop babysitting the nannis they hired for their clinical trials?
SCOPE continues to be a central location for industry colleagues to meet and exchange ideas around clinical development. We had a great time at the 2020 meeting catching up with friends, clients and colleagues, as well as co-moderating a roundtable on protocol design and chairing a main session on site selection with esteemed industry practitioners.
Less artificial…more intelligence
In the industry of clinical research, we are accustomed to working with conservative companies that make decisions slowly. Look at the adoption of EDC – over how many decades now? Understandable, at least to a point.
Delivering nash trials in a competitive world using clinsite
Site effectiveness index: a strategically important metric in clinical trial planning
The importance of site activation planning and implementation is a given among those who develop and manage clinical trials.
Using data analytics to evaluate clinical trial network performance: a look “under the hood”
As the clinical research environment becomes more complex and competitive, pharmaceutical companies are increasingly relying on networks of physicians to conduct their critical trials.